HC Wainwright Forecasts Increased Earnings for Cytokinetics

Cytokinetics, Incorporated (NASDAQ:CYTK) – HC Wainwright increased their FY2026 earnings per share estimates for Cytokinetics in a research report issued on Thursday, November 5th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings per share of ($5.89) for the year, up from their prior estimate of ($6.38). HC Wainwright has a “Buy” rating and a $140.00 price objective on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.84) per share. HC Wainwright also issued estimates for Cytokinetics’ Q4 2026 earnings at ($1.37) EPS, FY2027 earnings at ($5.07) EPS and FY2028 earnings at ($1.84) EPS.

Several other research analysts have also recently commented on the stock. Wall Street Zen upgraded shares of Cytokinetics from a “sell” rating to a “hold” rating in a research report on Saturday. Truist Financial boosted their price objective on Cytokinetics from $106.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Leerink Partners reduced their price objective on Cytokinetics from $103.00 to $100.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. Barclays increased their price objective on Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Finally, Morgan Stanley upgraded Cytokinetics from an “overweight” rating to a “buy” rating in a research report on Tuesday, September 1st. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.67.

Cytokinetics Stock Up 1.9%

Cytokinetics stock opened at $56.18 on Monday. The firm has a 50-day moving average price of $65.04 and a two-hundred day moving average price of $69.88. The firm has a market capitalization of $7.83 billion, a price-to-earnings ratio of -9.30 and a beta of 0.45. Cytokinetics has a 52-week low of $53.55 and a 52-week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) EPS for the quarter, topping the consensus estimate of ($1.43) by $0.06. The firm had revenue of $47.56 million for the quarter, compared to the consensus estimate of $41.88 million. During the same quarter in the prior year, the company posted ($2.55) EPS. The firm’s revenue was up 2356.5% on a year-over-year basis.

Institutional Investors Weigh In On Cytokinetics

A number of institutional investors have recently added to or reduced their stakes in CYTK. Private Advisor Group LLC lifted its holdings in shares of Cytokinetics by 27.5% in the third quarter. Private Advisor Group LLC now owns 9,233 shares of the biopharmaceutical company’s stock valued at $609,000 after buying an additional 1,991 shares during the period. Voya Investment Management LLC boosted its stake in Cytokinetics by 26.7% during the third quarter. Voya Investment Management LLC now owns 467,096 shares of the biopharmaceutical company’s stock valued at $30,786,000 after buying an additional 98,398 shares in the last quarter. Impax Asset Management Group plc grew its holdings in Cytokinetics by 21.2% during the third quarter. Impax Asset Management Group plc now owns 200,000 shares of the biopharmaceutical company’s stock worth $13,182,000 after acquiring an additional 35,000 shares during the period. Teachers Retirement System of The State of Kentucky grew its holdings in Cytokinetics by 0.8% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 66,875 shares of the biopharmaceutical company’s stock worth $4,408,000 after acquiring an additional 543 shares during the period. Finally, Carlson Capital L.P. grew its holdings in Cytokinetics by 33.3% during the third quarter. Carlson Capital L.P. now owns 12,000 shares of the biopharmaceutical company’s stock worth $791,000 after acquiring an additional 3,000 shares during the period.

Insider Activity at Cytokinetics

In other news, EVP Fady Malik sold 3,500 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $75.46, for a total value of $264,110.00. Following the completion of the transaction, the executive vice president directly owned 153,902 shares in the company, valued at $11,613,444.92. This trade represents a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $70.24, for a total transaction of $702,400.00. Following the transaction, the executive vice president owned 58,555 shares in the company, valued at $4,112,903.20. This represents a 14.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 173,426 shares of company stock worth $11,934,640 in the last 90 days. Corporate insiders own 2.60% of the company’s stock.

Cytokinetics Company Profile

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.